← All trials
NCT04212091
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2020
- Primary completion
- Feb 10, 2022
- Completion date
- Feb 10, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 32
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of North Carolina at Chapel HillStudy chair
- Emory UniversityStudy chair
- HIV Vaccine Trials NetworkCollaborator
- HIV Prevention Trials NetworkCollaborator
- Harvard UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.